drugset / Trial / NCT06699576
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
NaSequentialOpen-labelTreatment
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced bone and soft tissue sarcoma.
Timeline
- Start
- 2024-12-20
- Primary completion
- 2026-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | Intravenous |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Epirubicin | Small molecule | — | Intravenous |
| Subject | HS-20093 | Other / unclassified | — | Intravenous |